King Tigan 300 Mg Promos Planned After FDA Trimethobenzamide Notice

King Pharmaceuticals plans to begin promoting Tigan 300 mg for the treatment of gastroenteritis after remaining trimethobenzamide products are withdrawn from the market

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet